Across TCGA pan-cancer cohorts, MIR1197 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated MIR1197 data layer compared with 1 for mutation status.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher MIR1197 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MIR1197 expression acts as an unfavorable survival marker, although some lineages such as LAML and GBM show a favorable association.

LAML, STAD, and GBM are the cancer types where MIR1197 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Tertile	All	0.878	0.337	.006	30	view →
STAD	DFS	Tertile	All	0.211	0.709	.015	12	view →
GBM	OS	Tertile	All	1.000	0.308	.046	9	view →
PCPG	OS	Tertile	All	0.888	1.000	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIR1197 tumor-vs-normal RNA expression · all MIR1197 data types